Ionis Pharmaceuticals, Inc. Number of Reportable Segments
Ionis Pharmaceuticals, Inc. (IONS) reported Number of Reportable Segments of 1 Segment for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Notes › Segment Reporting
us-gaap:NumberOfReportableSegments · last filed 2026-07-29
- Ionis Pharmaceuticals, Inc. number of reportable segments for the quarter ending 2026-03-31 was 1.00 Segment.
- Ionis Pharmaceuticals, Inc. number of reportable segments for the quarter ending 2020-03-31 was 2.00 Segment, a 0.00% change year-over-year.
- Ionis Pharmaceuticals, Inc. number of reportable segments for the quarter ending 2019-03-31 was 2.00 Segment, a 0.00% change year-over-year.
- Ionis Pharmaceuticals, Inc. number of reportable segments for the quarter ending 2018-03-31 was 2.00 Segment, a 0.00% change year-over-year.
- Ionis Pharmaceuticals, Inc. number of reportable segments for fiscal 2025 was 1.00 Segment.
- Ionis Pharmaceuticals, Inc. number of reportable segments for fiscal 2020 was 2.00 Segment, a 0.00% change from fiscal 2019.
- Ionis Pharmaceuticals, Inc. number of reportable segments for fiscal 2019 was 2.00 Segment, a 0.00% change from fiscal 2018.
- Ionis Pharmaceuticals, Inc. number of reportable segments for fiscal 2018 was 2.00 Segment, a 0.00% change from fiscal 2017.
Segment
| Period end | Number of Reportable Segments 3 month | Number of Reportable Segments 6 month | Number of Reportable Segments 9 month | Number of Reportable Segments 12 month |
|---|---|---|---|---|
| 2026-06-30 | 1.00 Segment 10-Q · filed 2026-07-29 | |||
| 2026-03-31 | 1.00 Segment 10-Q · filed 2026-04-29 | |||
| 2025-12-31 | 1.00 Segment 10-K · filed 2026-02-26 | |||
| 2020-12-31 | 2.00 Segment 10-K · filed 2021-02-24 | |||
| 2020-09-30 | 2.00 Segment 10-Q · filed 2020-11-04 | |||
| 2020-06-30 | 2.00 Segment 10-Q · filed 2020-08-05 | |||
| 2020-03-31 | 2.00 Segment 10-Q · filed 2020-05-06 | |||
| 2019-12-31 | 2.00 Segment 10-K · filed 2020-03-02 | |||
| 2019-09-30 | 2.00 Segment 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | 2.00 Segment 10-Q · filed 2019-08-08 | |||
| 2019-03-31 | 2.00 Segment 10-Q · filed 2019-05-09 | |||
| 2018-12-31 | 2.00 Segment 10-K · filed 2019-03-01 | |||
| 2018-09-30 | 2.00 Segment 10-Q · filed 2018-11-06 | |||
| 2018-06-30 | 2.00 Segment 10-Q · filed 2018-08-07 | |||
| 2018-03-31 | 2.00 Segment 10-Q · filed 2018-05-07 | |||
| 2017-12-31 | 2.00 Segment 10-K · filed 2018-02-28 | |||
| 2017-09-30 | 2.00 Segment 10-Q · filed 2017-11-07 | |||
| 2017-06-30 | 2.00 Segment 10-Q · filed 2017-08-09 | |||
| 2017-03-31 | 2.00 Segment 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | 2.00 Segment 10-K · filed 2017-03-01 | |||
| 2016-09-30 | 2.00 Segment 10-Q · filed 2016-11-09 | |||
| 2016-06-30 | 2.00 Segment 10-Q · filed 2016-08-09 | |||
| 2016-03-31 | 2.00 Segment 10-Q · filed 2016-05-05 | |||
| 2015-12-31 | 2.00 Segment 10-K · filed 2016-02-26 | |||
| 2015-09-30 | 2.00 Segment 10-Q · filed 2015-11-09 | |||
| 2015-06-30 | 2.00 Segment 10-Q · filed 2015-08-05 | |||
| 2015-03-31 | 2.00 Segment 10-Q · filed 2015-05-05 |
pure
| Period end | Number of Reportable Segments 9 month |
|---|---|
| 2025-09-30 | 100.00% 10-Q · filed 2025-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |